Saudi Arabia is in the midst of a national transformation under Vision 2030, a strategic roadmap for economic diversification and reducing the reliance on oil revenues. A key pillar of this strategy is the overhaul of the healthcare sector, with a primary focus on achieving national drug security. Within this framework, localization has transitioned from a simple policy to a strategic imperative for all life science and biopharma companies operating in the Kingdom.

Saudi Arabia’s pharmaceutical market is the largest in the MENA region. Despite this, the nation has historically depended on imports for a majority of its drug supply. Current localization initiatives have reduced import reliance from 80% in 2019 to approximately 70% in 2023, with the government’s official goal to localize 50% of the pharmaceutical industry by 2030. This objective is supported by a sophisticated policy framework under the Local Content and Government Procurement Authority (LCGPA): the Economic Participation Program (EPP), which directly ties a company’s commercial success in public tenders to its reinvestment into the Saudi economy. In this environment, localization is no longer an optional compliance task, it is essential to market entry, pricing, and long-term sustainability.